Key facts

Active Substance
upadacitinib
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0103/2019
PIP number
EMEA-001741-PIP06-18
Pharmaceutical form(s)
Prolonged-release tablet
Condition(s) / indication(s)
Treatment of vasculitides
Route(s) of administration
Oral use
Contact for public enquiries

AbbVie Ltd

E-mail: paediatricteam@abbvie.com
Tel. +44 (0)1628 408248

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

P/0103/2019: EMA decision of 25 March 2019 on the granting of a product-specific waiver for upadacitinib (EMEA-001741-PIP06-18)

How useful do you find this page?